secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-06-25T21:01:07+00:00
Accession:  0001193125-26-282994
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma stockholders elect Class III directors, ratify EY, approve say-on-pay
--------------------------------------------------------------------------------

- Saqib Islam, Phillip Schneider, Laura Shawver elected as Class III directors; Schneider received 38.5M for vs 27.5M withheld.
- Ernst & Young ratified as auditor for FY2026 with 79.5M for, 102k against.
- Advisory vote on NEO compensation approved with 57.3M for, 8.1M against, 622k abstain.
- Advisory vote selects 1-year frequency for future say-on-pay votes (52.1M votes) until 2032 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526282994/0001193125-26-282994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526282994/d26870d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-282994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer